{"id":"W3093923068","doi":"10.1016/s1470-2045(20)30436-8","title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":745,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université Laval; Centre Hospitalier de l’Université de Montréal","funders":"Merck Sharp and Dohme","keywords":"Axitinib; Medicine; Sunitinib; Renal cell carcinoma; Pembrolizumab; Interim analysis; Internal medicine; Clinical endpoint; Oncology; Population; Kidney cancer; Clinical trial; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003131532,0.002285804,0.004239344,0.0005607781,0.0006006578,0.001833711,0.001153991,0.002161811,0.01004356],"category_scores_gemma":[0.002430108,0.0008584244,0.00387186,0.0005529628,0.001316373,0.002315051,0.0006297067,0.005389512,0.00192803],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001284114,"about_ca_system_score_gemma":0.001291393,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001711044,"about_ca_topic_score_gemma":0.0043964,"domain_scores_codex":[0.9989148,0.0005787715,0.00004633615,0.0001941556,0.00006901834,0.0001968523],"domain_scores_gemma":[0.9986933,0.0003857687,0.0002580294,0.0001156432,0.00007442509,0.0004729628],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9809881,0.002824141,0.0002705517,0.000498054,0.001127664,0.00002575478,0.00004857141,0.0004596472,0.001179102,0.00007121005,0.0008602381,0.01164685],"study_design_scores_gemma":[0.9532052,0.04358189,0.001408261,0.00003887549,0.0005019762,0.00003356345,0.00002436044,0.0003130916,0.0001987944,0.0001684259,0.0005096729,0.0000158663],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9783593,0.00876496,0.0008369214,0.001238563,0.001030975,0.002769067,0.002697514,0.0002374464,0.004065208],"genre_scores_gemma":[0.9803389,0.00402121,0.001640843,0.00181473,0.0006488236,0.002519064,0.002888504,0.00006182494,0.006066147],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01004356,"threshold_uncertainty_score":0.03359908,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1632971678821501,"score_gpt":0.3918027228166789,"score_spread":0.2285055549345288,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}